Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-24-098574
Filing Date
2024-11-14
Accepted
2024-11-14 17:20:45
Documents
7
Effectiveness Date
2024-11-14

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0220598-s8_oruka.htm S-8 69241
2 OPINION OF GIBSON, DUNN & CRUTCHER LLP ea022059801ex5-1_oruka.htm EX-5.1 11136
3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea022059801ex23-1_oruka.htm EX-23.1 1892
4 FORM OF GRANT NOTICE FOR STOCK OPTION AND STANDARD TERMS AND CONDITIONS FOR STOC ea022059801ex99-2_oruka.htm EX-99.2 43299
5 FORM OF GRANT NOTICE FOR STOCK OPTION AND STANDARD TERMS AND CONDITIONS FOR STOC ea022059801ex99-3_oruka.htm EX-99.3 44993
6 FILING FEE TABLE ea022059801ex-fee_oruka.htm EX-FILING FEES 22317
7 GRAPHIC ex5-1_001.jpg GRAPHIC 8140
  Complete submission text file 0001213900-24-098574.txt   205573
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-283243 | Film No.: 241464394
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)